BioInvent International recently announced promising interim results from one of its ongoing Phase IIa trials. The data shows that the company's lead drug candidate, BI-1808, in combination with Keytruda, achieved an overall response rate of 24 per cent in heavily pre-treated ovarian cancer patients – a result that stands out in a patient group with few effective treatment options. To learn more, BioStock turned to CEO Martin Welschof for a comment.
Read the full article at biostock.se:
https://biostock.se/en/2026/01/bioinvent-rapporterar-lovande-respons-vid-aggstockscancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se